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Biomarkers for personalized transplantation 
medicine
In 2010, 28,663 transplantations were performed in the 
United States. Currently, more than 100,000 US patients 
are  waiting  for  an  organ  transplant,  and  each  month 
approximately 4,000 patients are added (Organ Procure­
ment  and  Transplantation  Network  data  as  of  April 
2011). A significant number of patients on the waiting list 
are added due to functional failure of a first transplant, 
reflecting our current inability to ensure long­term allo­
graft  function  and  survival  and  representing  a  major 
problem in transplantation medicine.
The  major  reason  for  late  allograft  loss  is  chronic 
allograft damage (CAD), seen as the progressive decline 
of graft function >1 year post­transplantation. The under­
lying  mechanisms  of  CAD  are  poorly  understood  and 
need to be unraveled if graft function and treatment are 
to be successful. The definition of valid pre­ and post­
transplantation  biomarkers  will  facilitate  personalized 
transplantation  medicine,  leading  to  long­term  graft 
survival  and  decreasing  numbers  of  patients  on  the 
waiting list.
Identification of biomarkers will aid the understanding 
of  underlying  mechanisms  by  indicating  damage  early 
post­transplantation  when  pathological  changes  are 
taking place at the molecular level. This will enable us to 
better predict the likelihood of an individual’s allograft 
survival  and  assist  the  development  of  currently  un­
available treatments for CAD. Biomarkers will also allow 
better matching of donor and recipient and the assess­
ment  of  an  individual’s  risk  for  graft  injury.  Current 
methods  for  diagnosing  graft  injury  require  invasive 
biopsies and detect pathological changes at advanced and 
often irreversible stages of allograft damage. The use of 
more  sensitive  and  specific  methodologies  based  on 
donor and recipient genotyping, and transcriptional and 
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stages of organ injury would bridge this gap. This high­
lights the importance of ­omics­based approaches for the 
improvement of transplant practice.
Nowadays,  biomarker  studies  increasingly  integrate 
information from multiple platforms, such as genotype 
analyses  of  single­nucleotide  polymorphisms  (SNPs), 
epigenetic  studies  and  analyses  of  mRNA,  microRNA 
(miRNA),  as  well  as  protein,  peptide,  antibody  and 
metabolite  profiling.  High­throughput  analyses  are 
becom  ing more accessible, affordable and customizable, 
and  rapid  developments  in  analytical  tools  now  allow 
integrated  meta­analyses  of  different  datasets  across 
differ  ent experiments, platforms and technologies [1­4]. 
Functional  biomarker  studies  require  a  discovery  and 
several  validation  stages,  including  horizontal  and 
vertical meta­analyses and prospective validation. By this 
means, several potential biomarkers have been identified. 
However,  advances  towards  regulatory  application, 
approval and clinical implementation have been slow and 
costly, partly because of the difficulties faced in externally 
and prospectively validating these biomarkers.
Here,  we  concentrate  on  recent  advances  made  in 
transplantation biomarker medicine, focusing on the key 
stages of the biomarker development process. We high­
light  both  laboratory  test­based  and  clinically  applied 
pre­  and  post­transplantation  genomic,  transcriptomic 
and proteomic biomarkers of acute and chronic allograft 
injury  and  graft  accommodation.  We  point  out  the 
advantages and pitfalls of trying to identify non­invasive 
blood­based biomarkers and present recent approaches 
to  overcoming  related  obstacles.  Finally,  we  critically 
discuss  the  current  status  of  transplant  biomarker 
research along the road to clinical application.
Identification of clinically relevant biomarkers
The number of biomarker studies performed so far with 
respect to solid organ transplantation exceeds 15,000, yet 
the  number  of  resulting  US  Food  and  Drug  Adminis­
tration (FDA) approved biomarker­based diagnostic tests 
in transplantation stands at two, one being a functional 
immune assay and the other a non­invasive test based on 
blood gene expression for predicting the absence of acute 
allograft  rejection  (AR)  after  heart  transplantation  [5]. 
Needless to say, the path from discovery and validation of 
a biomarker in the academic laboratory to its approval 
for  the  clinic  is  torturous.  Well­thought­out  validation 
and  prospective  feasibility  studies  are  needed  to  move 
the biomarker discovery process towards FDA appli  ca­
tion, approval and clinical implementation (Figure 1).
The initial key steps in biomarker development are the 
discovery phase and the validation phase. In the dis  covery 
phase, usually high­throughput technologies on multiple 
molecular platforms and subsequent biostatistical analyses 
identify a first biomarker panel, which often comprises 
several  hundreds  of  candidates.  The  platforms  and 
molecular techniques used in this phase, such as DNA, 
RNA, miRNA microarray or antigen­based proto­arrays, 
usually generate large quantities of data; these method  o­
lo  gies  have  recently  been  reviewed  by  us  in  detail  [6]. 
Mandatory data deposition in the public domain, such as 
into the Gene Expression Omnibus (GEO), increasingly 
allows the use of publicly available data for the biomarker 
discovery phase and the use of new patient samples for 
the  validation  phase.  Pathway  and  network  analyses 
enable  integration  of  experimental  data  into  biological 
and cellular contexts, and by studying cellular crosstalk 
and molecular interactions, pathological pathways can be 
better elucidated [1­4]. In the near future, data obtained 
by  next­generation  sequencing,  copy  number  variation 
analyses and SNP arrays will be added.
The  discovery  phase  is  followed  by  one,  or  most 
frequently,  two  or  three  validation  phases  to  increase 
sensi  tivity  and  specificity.  The  first  validation  phase 
analyzes  the  initial  biomarker  panel  in  independent 
samples, leading to a refined set often consisting of 50 to 
100  candidates.  Meta­analyses  improve  the  sensitivity 
and  specificity  of  the  initial  candidate  set,  integrating 
results from different, often publicly available datasets. 
Horizontal  approaches  investigate  the  same  molecular 
platform  in  different  organs  [7­10],  and  vertical  meta­
analyses involve integration between different platforms, 
as in proteogenomic studies [11­13]. The advantages of 
meta­analyses  are  increased  sample  sizes  and  reduced 
experimental work, which help to increase the specificity 
and  sensitivity  of  the  initial  biomarker.  For  example,  a 
putative gene­based fingerprint in peripheral blood for 
kidney  transplant  tolerance  was  identified  using  this 
approach [14]. Information from the statistical analysis of 
microarrays (SAM) and predictive analysis of microarray 
(PAM)  techniques  identified  an  initial  biomarker  set, 
which was then cross­validated in independent samples 
and  further  refined  in  sample  data  from  different 
microarray platforms [15].
However,  the  comparability  of  data  from  different 
labora  tories has to be ensured and different laboratory 
procedures,  inter­center  variations  and  array  perfor­
mance on different days and when performed by different 
people  have  to  be  corrected  for.  For  this  purpose,  the 
microarray quality control (MAQC) studies [16,17] were 
initiated. These consisted of two phases aiming to provide 
quality control tools, develop data analysis guidelines and 
assess  limitations  and  capabilities  of  various  predictive 
biomarker models. As a result, common practices for the 
development and validation of microarray­based classifier 
models  were  defined  and  guidelines  for  global  gene 
expression analysis established. A third phase is under­
way, focusing on next­generation sequencing techniques.
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marker panel needs to undergo prospective validation in 
the clinical setting to establish the sensitivity, specificity 
and  negative  and  positive  predictive  values  for  clinical 
application. The organizational challenges and expense of 
conducting  prospective  observational  or  interventional 
studies on biomarkers are reflected by the fact that, so far, 
only few studies have reached this status in the biomarker 
development  process  [5,18,19].  Increased  numbers  of 
patients and samples need to be investigated for a long 
period, often for a minimum of 2 years, before clinically 
relevant conclusions can be made. These studies require 
skilled staff and financial resources as well as sufficient 
laboratory  infrastructure.  Most  importantly,  the  health 
and safety of patients and transplant organs remain the 
first  priority,  and  prospective  studies  often  carry 
unpredicted risks.
Identifying confounders
Another step towards confirming the clinical usefulness 
of a biomarker is to identify and control for experimental 
confounders.  Confounders  include  sample  bias,  tech­
nology bias and patient bias. A peripheral blood­based 
transcriptomic  biomarker  has  the  advantage  of  being 
minimally invasive and assessable on a frequent basis at 
reduced  cost  and  risk  compared  to  biopsied  samples. 
Importantly, a peripheral transcriptomic biomarker might 
also be measurable early, when no or minimal allograft 
damage has taken place. However, most cellular compo­
nents of peripheral blood respond quickly to exogenous 
Figure 1. Outline of the biomarker development process in the US from clinic to bench and back to clinic. As in drug development, the key 
phases are the discovery and validation phases, which involve complex FDA-regulated processes. (a) High-throughput, often in silico technologies 
are used to discover genomic, transcriptomic, proteomic or integrative investigational biomarkers, which are then (b) redefined in several validation 
phases using independent samples, technologies, and horizontal and vertical meta-analyses. (c) A clinically applicable biomarker assay based on 
good manufacturing practice (GMP) can be developed after prospective studies have confirmed the investigational biomarker. The FDA has to 
approve clinical studies, and only after successful completion and additional FDA regulation can the biomarker be considered valid and (d) be 
implemented into the clinic.
Phase 1
Initial validation 
phase 1
Meta-analyses
(independent sample sets
from public databases)
Confounder analyses
(sample bias, technology
bias, patient bias)
Pathway analyses
Gene-set enrichment
analyses Investigational
biomarker
panel II
Cross
validation
phase 2 
Prospective
validation 
phase 3
Independent samples
(Cross organ, integrative
intertechnological)
MA back validation
Microarray quality control
Clinical setting
independent, serial samples
Process optimization 
Phase 2+3
Clinical phenotype
Discovery phase
(high throughput)
Transcriptome
mRNA, miRNA, siRNA
(Gene regulation)
Proteome/metabolome
Proteins
(Gain/loss of function) 
Genome DNA
(Epigenetics, SNPs)  
Informatics
statistics
Investigational biomarker panel I
Biology
Validation
Blood Biopsy
Urine
Recipient/donor
biomaterial
Refinement
Clinical phase
Valid
biomarker 
Biomarker
assay
Sensitivity
specificity
GMP
NIB application
FDA/NIH
Causality test    
New biomarker
application 
New
investigational
biomarker
   (NIB)
Clinical
implemen
-tation 
Demographic/
clinical data 
(a)
(b)
(c)
(d)
Roedder et al. Genome Medicine 2011, 3:37 
http://genomemedicine.com/content/3/6/37
Page 3 of 12stimuli,  such  as  temperature  changes  or  shear  force, 
inducing  changes  in  gene  expression  ex  vivo.  In  this 
regard,  a  hypoxia­associated  gene  expression  signature 
was  detected  in  peripheral  blood  mononuclear  cells 
(PBMCs) after delayed sample processing compared to 
immediate sample processing [20].
Different  laboratory  techniques  for  sample  allocation 
and  handling  make  comparison  of  results  difficult,  or 
even  lead  to  controversial  results  [21­27].  This  aspect 
becomes  particularly  important  in  multi­center  studies 
or when using publicly available data from independently 
performed studies. Therefore, safe, quick and easy hand­
ling  during  sample  procurement  must  be  ensured  to 
minimize the overall impact of ex vivo changes to gene 
expression.  Currently  there  are  no  uniform  sample 
procure  ment  guidelines.  Several  studies  have  been 
addressing this issue [20,28,29].
The complex composition of samples useable for non­
invasive tests, such as blood and urine, make the identi  fi­
cation  of  valid  biomarkers  difficult.  For  example,  the 
abundant presence of globin mRNA as well as the hetero­
geneous nature of blood are important internal con  found­
ing factors to be controlled for when trying to identify a 
blood­based biomarker. Globin mRNA leads to decreased 
percentage present calls, decreased call concordance and 
increased  signal  variation  when  analyzing  whole­blood 
gene expression profiles by microarray. Debey et al. [30] 
presented  a  method  of  combined  whole­blood  RNA 
stabilization  and  globin  mRNA  reduction  followed  by 
genome­wide transcriptome analysis. We also reported 
[31] the interference of globin mRNA when using whole 
blood for the discovery of peripheral biomarkers of acute 
renal allograft rejection. A comparison of four different 
protocols for total RNA preparation, amplification and 
synthesis  of  complementary  RNA  or  cDNA  and  array 
hybridization revealed that only a combination of globin 
mRNA  reduction  during  handling  together  with  a 
mathematical  algorithm  provided  depletion  of  globin 
mRNA expression. This approach improved the detection 
of biological differences between blood samples collected 
from  patients  with  biopsy­proven  AR  or  stable  graft 
function [31].
Another obstacle in identifying a blood­based bio  marker 
is  the  heterogeneity  of  blood.  A  typical  blood  sample 
contains a large number of cell types, each with its own 
distinct expression profile [32]. Heterogeneity is further 
compounded by the frequency of the same cell type being 
different  between  individuals  [33].  Consequently,  a 
differential  expression  profile  observed  in  whole  blood 
between  two  phenotypes  could  be  caused  by  either  a 
change in frequency of a specific type of cell without a 
change in the expression profiles of each cell type or a 
change in the expression profile of a cell type while the 
frequency  of  the  cell  type  remains  constant.  Although 
one  way  to  address  this  issue  is  to  isolate  subsets  of 
specific cell types (for example, using cytometry or laser 
capture  microdissection)  and  profile  them,  such  tech­
niques  are  expensive,  time  consuming  and  limited  by 
difficulties  in  obtaining  sufficient  purified  tissue  with 
adequate RNA, and they may affect cell physiology and 
gene expression [20,34]. To address these challenges, we 
and others have proposed several statistical approaches 
to deconvoluting gene expression profiles from hetero­
geneous tissues [35­37]. Using a deconvolution approach, 
we  showed  [35]  that  although  whole­blood  expression 
profiles  did  not  reveal  differential  expression  between 
patients with AR and those with stable transplant func­
tion,  cell­type­specific  expression  profiles  estimated  by 
deconvolution  of  microarray  data  identified  dramatic 
changes in two cell types that would have otherwise been 
completely missed. Differentially expressed genes in AR 
and stable transplant patients at a false discovery rate of 
0.05  were  identified  between  lymphocytes  and  neutro­
phils,  as  well  as  137  upregulated  genes  in  monocytes 
from the AR patients.
Laboratory test-based biomarkers in 
transplantation medicine
Currently, a match between the human leukocyte antigen 
(HLA) in the sera of the donor and the recipient is the 
best pre­transplant biomarker [38]. Yet even in the case 
of a total match, the risk of clinical or subclinical AR and 
or CAD cannot be excluded. Post­transplant biomarkers 
include functional parameters that are mainly measured 
at the protein level, such as serum creatinine. The current 
gold  standard  to  differentially  diagnose  allograft 
pathologies  is  the  histological  assessment  of  invasive 
graft biopsies. The threshold indicating allograft damage 
by current post­transplant biomarkers is high and reached 
at a point when significant damage has already occurred 
(Figure 2). Therefore, biomarkers for predicting the risk of 
damage  or  for  indicating  preclinical  damage  at  the 
molecular level are needed. Applications that require an 
invasive biopsy limit the clinical applicability of identified 
biomarkers,  and  functional  monitoring  assays  that  use 
non­invasive samples, such as peripheral blood or patient 
urine, are more favorable (for patients and economically).
Pre-transplantation biomarkers
Genomic  analysis  of  donor  and  recipient  peripheral 
blood  DNA  before  transplantation  has  identified  SNPs 
that indicate the risk or severity of allograft damage or 
predict allograft survival, and these markers are useful at 
the pre­transplantation stage [39]. Mutations in the innate 
immune system protein Toll­like receptor in donor and/or 
recipient  blood  were  associated  with  reduced  risk  and 
severity  of  allograft  rejection  in  liver,  lung  and  kidney 
transplantation  [40­45],  and  complement  factor  C3 
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[46], further supporting the relevance of innate immunity 
for  transplantation  outcome.  However,  the  success  of 
SNP­based studies is often hindered by the need for large 
numbers  of  samples.  Using  samples  across  multiple 
centers might overcome this problem but results in inter­
center variation. This variation has been successfully over­
come  by  using  statistical  approaches,  and  a  biomarker 
panel  of  ten  SNPs  for  predicting  AR  was  identified 
(Table  1a).  Pre­transplantation  transcriptome  analyses 
have shown significant differences in C3 gene expression 
between  living  and  deceased  donors,  and  these 
differ  ences  were  directly  related  to  the  length  of  cold 
ischemia.  Cold  ischemia  during  transplantation  begins 
with the perfusion of the graft after procurement, which 
decreases the organ temperature due to the absence of 
blood  supply  and  creates  an  environment  of  hypoxia. 
Cold  ischemia  for  living  donor  transplantation  was 
significantly  shorter  than  that  for  deceased  donor 
transplantation,  and  changes  in  C3  gene  expression 
correlated with 2­year graft function [47].
More recently, the detection of novel antigens located 
in allograft tissue that drive allograft damage has been 
another means to predict AR before the development of 
Figure 2. Biomarkers in transplantation medicine. The application of biomarkers in transplantation medicine is very sensitive to time. Allograft 
damage progresses with time after transplantation, and the earlier allograft damage is detected, the better the chances for long-term allograft 
function become. Transplantation is the process that initiates the changes that lead to allograft damage. Post-transplantation biomarkers are 
dynamic, and the current post-transplantation biomarkers have a high threshold, allowing clinical diagnoses only long after transplantation 
damage, when changes are clinically and histologically manifested. Novel post-transplantation biomarkers require high sensitivity and a low 
threshold to indicate allograft damage pre-clinically; examples include non-invasive transcriptomic or proteomic biomarkers that will be applied 
to diagnose pathologies, to predict rejection, functional outcome, or the individual patient’s response to immunossupression. Other applications 
include targets for novel therapeutic interventions New pre-transplantation biomarkers are stable and are needed to indicate a patient’s baseline 
risk for damage or graft accommodation after transplantation. New pre-transplantation biomarkers are also needed to predict graft rejection and/or 
accommodation or the response to immunosuppression.
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Page 5 of 12corresponding antibodies in the serum. Integrative pro­
teo  genomic analyses have identified tissue­specific novel 
non­HLAs  that  led  to  serological  responses  in  renal 
trans  plant patients. Antibodies against MHC class I poly­
peptide related sequence A (MICA) in the recipients that 
recognized antigens specific to the renal pelvis and the 
renal cortex were identified [12]. The association of such 
novel non­HLA antigens with clinically relevant pheno­
types  could  identify  specific  immunogenic  epitopes  in 
AR and CAD [12,48­50].
Post-transplantation biomarkers
Transplantation  initiates  the  processes  responsible  for 
AR and CAD (Figure 2). Biomarkers of different subtypes 
of rejection injury in the graft itself that indicate damage 
at the molecular level are needed and could help distin­
guish rejection episodes with high versus low probability 
of  full  functional  recovery  after  anti­rejection  therapy 
[51].  Similarly,  biomarkers  for  graft  accommodation 
could lead to reduction of immunosuppressive drugs or 
identification of novel drug targets.
Biomarkers of acute allograft rejection
Advances in immunosuppressive therapy and improved 
patient monitoring have decreased the incidence of AR in 
solid  organ  transplantation.  However,  the  lack  of  non­
invasive biomarkers makes early diagnosis and optimized 
treatment regimens difficult, leading to approximately 10 
to  30%  of  all  transplant  patients  being  diagnosed  and 
treated  for  AR  episodes  within  the  first  year  after 
Table 1. Laboratory-based biomarkers
  Organ  Sample  Proposed mechanism  Biomarker  References
(a) Pre-transplantation biomarkers
Kidney, lung, liver Blood (DNA) Genetic variants in donor/recipient are associated 
with risk and severity of AR and with allograft 
survival
15 SNPs, TLR, C3 [39,40-
44,46]
Kidney Biopsy (mRNA) Expression profiles of innate immunity-related genes 
predict allograft survival
C3  [47]
Kidney Serum (protein); 
biopsy (mRNA)
Novel immunogenic epitopes  Non-HLA antigens  [12,48-50]
(b) Post-transplantation biomarkers: acute allograft rejection
Kidney Blood (PBMCs, 
mRNA), urine (mRNA)
Cytotoxic proteins indicate AR  FasL, GranzymeB, Perforine  [27,54,57-
58]
Kidney, lung, liver, 
heart
Blood (PBMCs), 
serum, BALF, urine 
(mRNA, protein)
Donor/recipient cytokine expression predicts/
detects AR 
CXCR, CXCL10 CXCL9 [59-63]
Kidney Biopsy, blood 
(PBMCs, mRNA)
Alterations in miRNA are associated with AR  miR-142-5p, miR-155, miR-223 [64-67]
Kidney Biopsy Biomarkers for antibody-mediated rejection 
(diagnostic/predictive)
CD38, endothelial cell genes [70,71]
Kidney Biopsy, serum 
(protein)
Antibodies against novel non-HLA antigens 
(diagnostic/predictive)
AT1R-AA, MICA, Duffy, Kidd, Agrin [50,72-75]
Kidney, heart Biopsy, serum 
(mRNA, protein)
Integrative proteogenomic biomarkers predict and 
diagnose AR across organs
Novel non-HLA antigen PECAM1 [12,76]
Post-transplantation biomarkers: chronic allograft damage
Kidney Blood (mRNA), 
biopsy (mRNA), urine 
(mRNA)
Predictive peripheral genes and proteins for mild/
moderate chronic allograft damage and chronic 
antibody-mediated damage
TRIB1, CCL2 [13,77,82]
Kidney, heart Blood (protein), 
biopsy (mRNA), urine 
(protein)
Early diagnostic peripheral and urinary gene 
expression for IF/TA and anti-fibrotic target
KIM-1, CTGF [78,79, 
85,86]
Post-transplantation biomarkers: graft accommodation
Liver, kidney Blood (PBMCs, 
mRNA)
Peripheral gene expression identifies 
transplant recipients for discontinuation of 
immunosuppression 
(a) Three classifiers of 2,3 and 7 genes; 
(b) 33-gene panel;  
(c) 343 genes
[88,89]
Kidney Blood (mRNA) B-lymphocyte-related gene signature of tolerance in 
transplant patient PBMCs
(a) B-cell signature (IGKV1D-13, IGKV4-1, 
IGLL1); (b) B-cell signature, ratio of 
FOXP3/α-1,2-mannosidase
[90,91]
AT1R-AA, agonistic antibodies against angiotensin type II receptor 1; BALF, bronchoalveolar fluid; CCL, CC chemokine ligand; FasL, Fas ligand; FOXP3, Forkhead box 
P3; IGKV, immunoglobulin kappa variable group; IGLL1, immunoglobulin lambda-like polypeptide 1; KIM-1, kidney injury molecule 1; TLR, Toll-like receptor; IF/TA, 
interstitial fibrosis/tubular atrophy.
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undetected subclinical episodes. AR represents a major 
risk factor for long­term allograft dysfunction.
Among  the  first  non­invasive,  gene­expression­based 
cellular  AR  biomarkers  discovered  were  the  lethal 
chemo  kine perforine, tumor necrosis factor α, transmem­
brane  protein  Fas  ligand  and  the  serine  protease 
granzyme B, proteins involved in cytotoxic lymphocyte 
function  [27,54]  (Table  1a).  Several  whole­genome 
transcriptional studies using PBMCs or urine specimens 
from transplant patients showed that expression of these 
genes indicated cell­mediated AR. However, the results 
could not always be confirmed in gene expression studies 
using  graft  biopsies  or  geographically  distinct  sample 
sets.  In  addition,  the  differential  expression  of  these 
potential  markers  in  other  renal  diseases  limited  their 
feasibility as AR­specific biomarkers in kidney transplan­
ta  tion [21­23,55]. Only urinary cell transcriptional levels 
of perforin, granzyme B [56] and granulysin [57] were 
found  to  be  diagnostic  of  biopsy­proven  cell­mediated 
AR in renal transplant patients [58].
Other extensively studied potential biomarkers across 
liver, lung, kidney and heart transplants include chemo­
kines and cytokines. These molecules lead to the differen­
tiation,  migration  and  proliferation  of  immune  cells 
during AR. In this regard, the chemokines CXCL9 and 
CXCL10 and the chemokine receptor CXCR3 have been 
identified as potential biomarkers to predict AR and can 
be assessed in transplant patient serum, peripheral blood, 
urine and bronchoalveolar fluid. Other studies revealed 
their potential as novel therapeutic targets [59­63]. How­
ever, none of them has yet reached clinical trial status, 
and the relevance of these molecules needs to be deter­
mined in large cohort studies.
Other gene­expression­based AR biomarkers of increas­
ing interest are miRNAs. These are small (about 19 to 25 
nucleotides), naturally occurring noncoding RNAs that 
primarily repress the translation of mRNA or lead to its 
degradation  [64].  miRNAs  are  potential  biomarkers  in 
renal transplant patient biopsies and stimulated PBMCs 
[65].  miR­155  has  been  found  to  be  overexpressed  in 
PBMCs  from  AR  patients  [65]  and  to  enhance  the 
develop  ment of inflammatory T cells [66]. miRNAs can 
influence AR, CAD and induction of tolerance [67].
Proteomic  approaches  identified  urinary  protein  and 
peptide  biomarkers  that  can  correlate  with  AR.  These 
studies provided a powerful means to distinguish for the 
first  time  between  AR  and  BK  virus  nephropathy,  two 
conditions  that  seem  very  similar  when  biopsied  yet 
require opposing management strategies. A non­invasive 
urine­based test to distinguish between these entities is a 
major  advance  for  the  renal  transplant  field,  especially 
with  the  increasing  incidence  of  BK  virus  infection  in 
transplant recipients [68,69].
Antibody­mediated  AR  occurs  in  a  minority  of 
transplant patients and is characterized by the recipient’s 
B  lymphocytes  forming  antibodies  against  donor  anti­
gens.  Current  diagnosis  is  based  on  the  presence  of 
donor­specific  antibodies  in  the  periphery  and  on 
immunostaining for CD20 and peritubular deposition of 
complement­activated factor C4d. Recently, C4d­negative 
antibody­mediated AR episodes have been reported and 
asymptomatic episodes were associated with poor allo­
graft outcome. This potentially leads to higher numbers 
of actual antibody­mediated AR cases when assessed retro­
spectively,  further  strengthening  the  necessity  for  new 
biomarkers of rejection. Endothelial cell gene expres  sion 
in  kidney  transplant  biopsies  has  been  positively  asso­
ciated with the presence of antibody­mediated AR [70] 
and the presence of infiltrating clusters of CD38­positive 
plasmablasts,  which  correlated  better  with  antibody­
mediated rejection than with intragraft C4d staining [71].
Antibody­based  biomarkers  have  been  identified  by 
investigating non­HLA antigen responses after transplan­
ta  tion,  which  have  a  greater  role  in  allograft  outcome 
than previously thought and thus represent novel diag­
nostic and predictive biomarkers. Of note are the agonistic 
antibodies  against  the  angiotensin  II  type  1  receptor 
(AT1R­AA) described in renal allograft recipients with 
severe vascular types of AR [72]. Antagonistic antibodies 
against  MICA,  the  chemokine  receptor  Duffy,  Kidd 
polymorphic blood group antigens and the most abun­
dant heparin sulfate proteoglycan, Agrin, were associated 
with decreased allograft survival [50,73], chronic allograft 
damage [74] and the development of glomerulopathy [75].
In  an  integrative  approach  using  transcriptomic  and 
proteomic data, novel non­HLA antigens were identified 
as triggering de novo serological responses after trans­
plantation  in  renal  transplant  recipients  [12].  Interest­
ingly, the antigens with the highest immunogenic power 
were located in the renal pelvis of the allograft. In another 
integrative  study,  genes  coding  for  serum­  and  urine­
detectable proteins that were differentially expressed in 
renal and cardiac biopsies from AR patients were tested 
for their potential as diagnostic protein biomarkers in a 
cross­organ,  cross­platform  study.  Upregulated  platelet 
endothelial  cell  adhesion  molecule  1  (PECAM1)  in 
biopsies, serum and urine identified renal AR with 89% 
sensitivity  and  75%  specificity  in  a  cross­organ  study 
using publicly available microarray data [76].
Biomarkers for chronic allograft injury
In  contrast  to  AR,  chronic  allograft  injury  is  a  slow 
progressive  disorder  involving  complex  multistage 
molecular  processes,  which  can  be  seen  from  gradual, 
accumulative  changes  that  lead  to  declining  allograft 
function  after  1  year  post­transplantation  and  finally 
often  result  in  allograft  loss.  These  processes  remain 
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rate  of  changes  that  only  slowly  reveal  a  measurable 
phenotype,  and  by  increasing  post­transplantation 
external biases introduced by immunosuppressive treat­
ment,  associated  side­effects,  patient  compliance,  life­
styles  and  subclinical  processes,  often  resulting  in  in­
conclusive  findings.  As  a  result,  biomarkers,  and 
especially  non­invasive  biomarkers  specific  for  chronic 
allograft  injury,  are  sparse,  and  extremely  sensitive 
methods  are  needed  to  detect  relevant  changes  before 
they accumulate and become clinically detectable.
Non­invasive markers of CAD, including urinary and 
peripheral  biomarkers,  could  not  only  be  readily 
identified  and  validated  at  numerous  time­points  but 
would also allow regular monitoring over a long period of 
time at low cost and would be associated with low patient 
risk. In an attempt to correlate blood expression signa­
tures with biopsy­proven chronic allograft damage, gene 
expression panels were identified that predicted mild and 
moderate/severe chronic allograft damage, and Tribbles­1 
(TRIB1)  was  identified  to  predict  chronic  antibody­
mediated rejection [13,77]. Well studied molecules in the 
pathogenesis  of  fibrosis,  as  seen  in  chronic  allograft 
damage,  are  the  transforming  and  connective  tissue 
growth  factors  (transforming  growth  factor­β  and 
connective tissue growth factor (CTGF)) [78,79]. CTGF 
was increased in transplant patient urine before histo­
pathological and functional chronic dysfunction, reveal­
ing it as a potential early non­invasive biomarker [80] and 
as a potential antifibrotic target [81]. Urinary expression 
of the chemokine CCL2 at 6 months post­transplantation 
predicted the development of chronic allograft dysfunc­
tion at 24 months post­transplantation in 111 patients 
[82]. Kidney injury molecule 1 (KIM1), previously dis­
covered as a proximal tubular biomarker of acute kidney 
injury  [83,84],  was  associated  with  chronic  allograft 
damage, including calcineurin inhibitor toxicity and inter­
stitial  fibrosis/tubular  atrophy  [85,86].  However,  KIM1 
expression  also  correlated  with  transplant­indepen  dent 
drug­induced nephrotoxicity [87] and renal cell carcinoma 
[84], revealing it as a marker of general renal injury [83].
Biomarkers for monitoring graft accommodation
Achieving an immunosuppression­free state, referred to 
as clinical operational tolerance, is the ultimate goal in 
transplantation. Current estimates report only 100 cases 
of clinical operational tolerance in renal transplants so 
far [88] and tolerance induction protocols, such as peri­
operative infusion of donor bone­marrow­derived stem 
cells or perioperative lymphocyte depletion, have failed 
and  have  led  to  graft  loss  in  most  cases.  Specific 
biomarkers  indicating  immune  quiescence  and 
represent  ing  targets  for  novel  tolerance  induction 
protocols  are  needed.  In  a  recent  study  [89],  three 
gene­expression­based  classifiers  were  identified, 
predicting liver tolerance and identifying liver transplant 
recipients  for  discontinuation  of  immunosuppression. 
Here, a combined approach of microarray discovery and 
quantitative reverse transcriptase (qRT)­PCR validation 
using  PBMCs  from  a  total  of  44  tolerant  and  48  non­
tolerant patients was used [89] to determine a first gene 
expression signature of renal allograft tolerance consist­
ing  of  33  genes.  This  panel  was  able  to  predict  the 
presence of a peripheral tolerant phenotype suggesting a 
pattern  of  reduced  co­stimulatory  signaling,  immune 
quiescence, apoptosis and memory T cell responses [14].
Recently, two groups identified tolerance gene expres­
sion signatures in kidney transplant patients associated 
with B cells by applying the same microarray and qRT­
PCR approach [90,91]. Genes identified by Newell et al. 
[90] were associated with clinical and phenotypic para­
meters and with increased expression of multiple B­cell 
differentiation genes. The tolerance signature identified 
by Sagoo et al. [91] was also related to B cells, consisting 
of ten individual genes with a high ratio of the forkhead 
box  protein  FOXP3  to  α­1,2­mannosidase.  Tolerant 
patients showed an expansion of peripheral blood B and 
natural killer lymphocytes, fewer activated CD4+ T cells, 
a  lack  of  donor­specific  antibodies  and  donor­specific 
hyporesponsiveness of CD4+ T cells. Similar studies on 
operational tolerance have also been done in liver trans­
plant recipients [89]. Tolerance­associated gene­expression 
signatures  seem  to  be  promising,  as  validation  studies 
have  proven  their  relevance.  Whether  these  signatures 
can be used to predict or monitor tolerance in transplant 
patients has to be assessed in prospective studies using 
larger numbers of patients, which will be difficult given 
the low incidence of tolerance.
FDA-approved biomarkers
A  transcriptomic  analysis  of  peripheral  blood  samples 
from heart allograft patients identified an 11­gene panel 
that discriminated patients with stable allograft function 
from patients with moderate or severe AR [92], which led 
to  the  development  of  the  first  FDA­approved  non­
invasive diagnostic test for acute heart allograft rejection 
(AlloMap,  XDx).  Applying  a  mathematical  algorithm, 
gene  expression  was  translated  into  a  diagnostic  score 
[93] that discriminated stable transplants from AR and 
mild from severe AR. Another approach has exploited 
the measurement of the ATP release that depends on T­
cell  stimulation  (iATP)  [94­96],  hypothesizing  that  the 
activation status of T cells indicates patients at high risk 
of  acute  rejection  or  at  high  risk  for  over­  or  under­
immunosuppression. The iATP levels led to the develop­
ment of a therapeutic response assay, ImmuKnow (Cylex) 
[18,97­100]  (Table  2).  Nevertheless,  a  new  set  of  bio­
markers is desperately needed to replace or complement 
Roedder et al. Genome Medicine 2011, 3:37 
http://genomemedicine.com/content/3/6/37
Page 8 of 12these  tests  in  order  to  improve  clinical  practice  with 
regard to the function of transplanted organs. This will be 
achieved only with a biomarker panel ­ gene­ or protein­
based ­ that has high positive predictive value for injury 
(which  is  missing  in  the  AlloMap  panel)  and  has  very 
high  specificity  and  sensitivity  for  injury  (which  is 
missing in the Cylex test).
Conclusion}
The ultimate goal of biomarker studies in transplantation 
is to find non­invasive biomarkers of transplant patho­
logies using patient urine or blood that indicate changes 
at  the  molecular  level,  before  the  development  of  a 
clinical  phenotype,  that  predict  allograft  outcome  or 
response to therapy, and that possibly reveal novel targets 
for therapeutic interventions. As a result of the tech  no­
logical  advances  in  high­throughput  methodolo  gies, 
multiple biomarker studies have been performed, leading 
to  numerous  potential  biomarkers  being  pub  lished. 
However,  only  very  few  have  graduated  from  the 
laboratory and gained FDA approval.
Laboratory­dependent  confounding  factors  include 
differences  in  sample  processing  and  data  analyses, 
making comparability of data difficult. Regulatory elements 
and analytical guidelines, as suggested by the NIH or the 
MACQ  studies,  have  been  introduced  to  increase  the 
validity and robustness of identified biomarkers and to 
make  studies  more  homogenous.  Sample­dependent 
con  found  ing  factors,  such  as  the  abundance  of  globin 
mRNA in whole blood, have been identified and success­
fully overcome, and advances in analytical methods now 
allow horizontal and vertical meta­analyses.
Promising non­invasive biomarkers for acute rejection 
and operational tolerance have therefore been identified 
and  now  need  prospective  validation  in  large  patient 
cohorts. Multi­center studies have been introduced: the 
US ‘Clinical Trials in Organ Transplantation’ (CTOT and 
CTOTC), the Canadian ‘Biomarkers in Transplantation’ 
(BIT) project and the European study of ‘Reprogramming 
the  Immune  System  for  Establishment  of  Tolerance’ 
(RISET).
In addition, we have gained deeper knowledge about 
the underlying pathogenic mechanisms of AR and CAD. 
The detection of novel non­HLA antibodies, C4d­nega­
tive  antibody­mediated  rejection,  and  the  role  of  the 
innate immune system in acute rejection, as seen in the 
relevance  of  complement­system­associated  molecules, 
will further biomarker development.
As  seen  for  drug  development  studies,  biomarker 
development studies need to become more uniform and 
standardized. Standard operating procedures for sample 
handling, experimental procedures and performance of 
data  analyses  need  to  be  introduced,  in  addition  to 
requirements  for  sample  sizes,  number  and  kind  of 
validation studies.
Once transferred to the clinic, these recent advances 
will  eventually  lead  to  personalized  transplantation 
medicine, including improved donor­recipient matching, 
individual immunosuppressive regimens, and individual 
risk assessment for AR or CAD and prediction of graft 
accommodation. These improvements will undoubtedly 
reduce the costs of health care dramatically. Finally, these 
changes will be reflected by increased allograft survival 
and decreased patient morbidity.
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